1 Ocak 2010 Dergi makalesi Açık Erişim

Barbai, V. H.; Ujhelyi, E.; Szlavik, J.; Vietorisz, I.; Varga, L.; Fey, E.; Fust, G.; Banhegyi, D.

DataCite XML

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-4" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
  <identifier identifierType="URL">https://aperta.ulakbim.gov.tr/record/27023</identifier>
  <creators>
    <creator>
      <creatorName>Barbai, V. H.</creatorName>
      <givenName>V. H.</givenName>
      <familyName>Barbai</familyName>
      <affiliation>Fovarosi Onkormanyzat Egyesitett Szent Istvan &amp; S, Dept Immunol, H-1097 Budapest, Hungary</affiliation>
    </creator>
    <creator>
      <creatorName>Ujhelyi, E.</creatorName>
      <givenName>E.</givenName>
      <familyName>Ujhelyi</familyName>
      <affiliation>Fovarosi Onkormanyzat Egyesitett Szent Istvan &amp; S, Dept Immunol, H-1097 Budapest, Hungary</affiliation>
    </creator>
    <creator>
      <creatorName>Szlavik, J.</creatorName>
      <givenName>J.</givenName>
      <familyName>Szlavik</familyName>
      <affiliation>Fovarosi Onkormanyzat Egyesitett Szent Istvan &amp; S, Dept Trop Dis, H-1097 Budapest, Hungary</affiliation>
    </creator>
    <creator>
      <creatorName>Vietorisz, I.</creatorName>
      <givenName>I.</givenName>
      <familyName>Vietorisz</familyName>
      <affiliation>Fovarosi Onkormanyzat Egyesitett Szent Istvan &amp; S, Dept Clin Chem, H-1097 Budapest, Hungary</affiliation>
    </creator>
    <creator>
      <creatorName>Varga, L.</creatorName>
      <givenName>L.</givenName>
      <familyName>Varga</familyName>
      <affiliation>Semmelweis Univ, Dept Internal Med 3, Budapest, Hungary</affiliation>
    </creator>
    <creator>
      <creatorName>Fey, E.</creatorName>
      <givenName>E.</givenName>
      <familyName>Fey</familyName>
      <affiliation>Fovarosi Onkormanyzat Egyesitett Szent Istvan &amp; S, Dept Clin Chem, H-1097 Budapest, Hungary</affiliation>
    </creator>
    <creator>
      <creatorName>Fust, G.</creatorName>
      <givenName>G.</givenName>
      <familyName>Fust</familyName>
      <affiliation>Semmelweis Univ, Dept Internal Med 3, Budapest, Hungary</affiliation>
    </creator>
    <creator>
      <creatorName>Banhegyi, D.</creatorName>
      <givenName>D.</givenName>
      <familyName>Banhegyi</familyName>
      <affiliation>Fovarosi Onkormanyzat Egyesitett Szent Istvan &amp; S, Dept Trop Dis, H-1097 Budapest, Hungary</affiliation>
    </creator>
  </creators>
  <titles>
    <title>Changes In The Levels Of Some Acute-Phase Proteins In Human Immunodeficiency Virus-1 Infected Patients, Following Interleukin-2 Treatment</title>
  </titles>
  <publisher>Aperta</publisher>
  <publicationYear>2010</publicationYear>
  <dates>
    <date dateType="Issued">2010-01-01</date>
  </dates>
  <resourceType resourceTypeGeneral="Text">Journal article</resourceType>
  <alternateIdentifiers>
    <alternateIdentifier alternateIdentifierType="url">https://aperta.ulakbim.gov.tr/record/27023</alternateIdentifier>
  </alternateIdentifiers>
  <relatedIdentifiers>
    <relatedIdentifier relatedIdentifierType="DOI" relationType="IsIdenticalTo">10.1111/j.1365-2249.2010.04145.x</relatedIdentifier>
  </relatedIdentifiers>
  <rightsList>
    <rights rightsURI="http://www.opendefinition.org/licenses/cc-by">Creative Commons Attribution</rights>
    <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights>
  </rightsList>
  <descriptions>
    <description descriptionType="Abstract">P&amp;gt;Intermittent interleukin (IL)-2 administration to human immunodeficiency virus (HIV)-1 infected patients is well documented and generally used, but there is limited information about the changes of acute-phase protein (APP) levels in response to this treatment. Fifteen patients undergoing highly active anti-retroviral therapy (HAART) treatment, with undetectable viral load, but low CD4+ cell count (&amp;lt; 300/mu l), have been treated with 3 center dot 6 M IU Proleukine (R) administered twice daily by subcutaneous injection over 5 days. C-reactive protein (CRP), d-dimer, C3, C9, C1-inh and alpha-2HS glycoprotein levels were measured immediately before IL-2 administration, as well as on day 5 and 2-3 weeks thereafter. After IL-2 administration, both mean d-dimer and CRP levels increased significantly (P &amp;lt; 0 center dot 001), but returned (P &amp;lt; 0 center dot 001) to baseline within the subsequent 2-3 weeks. Alpha-2HS glycoprotein decreased immediately after IL-2 administration. No significant differences were detected in the levels of C3, C9 and C1-inh. A significant, positive correlation (r = 0 center dot 5178, P = 0 center dot 0008) was ascertained between the changes of CRP level, measured immediately before as well as 5 days after IL-2 administration, and changes in CD4 T cell counts measured 2-3 weeks before and after treatment, respectively. IL-2 administration induces rapid elevation of two major APPs (CRP, d-dimer). The positive correlation observed between the changes of CRP levels and CD4+ cell counts after IL-2 administration may indicate that the abrupt, but transitory overproduction of CRP might contribute to the CD4+ cell count-increasing effect of the drug and/ or may be associated with serious side effects.</description>
  </descriptions>
</resource>